Table 2.
Patient characteristics, treatment, and pathology of resectable distal cholangiocarcinoma
| Variable | Patients analyzeda (n) | n (%) or median (range) |
|---|---|---|
| Male | 176 | 108 (61.4) |
| Age (years) | 176 | 66 (33–87) |
| BMI (kg/m2) | 142 | 27 (16–70) |
| Preoperative clinical jaundice | 175 | 129 (73.3) |
| Resection | 176 | |
| Pylorus-preserving pancreaticoduodenectomy | 86 (48.9) | |
| Classic pancreaticoduodenectomy | 90 (51.1) | |
| Portal vein resection | 176 | 8 (4.5) |
| Tumor size (cm) | 176 | 2.1 (0.1–7.5) |
| Tumor size ≥1 cm | 176 | 161 (91.5) |
| Tumor size ≥2 cm | 176 | 107 (60.8) |
| Tumor size ≥3 cm | 176 | 42 (23.9) |
| Tumor size ≥4 cm | 176 | 11 (6.3) |
| Tumor size ≥5 cm | 176 | 7 (4.0) |
| Lymphovascular invasion | 176 | 90 (51.1) |
| Perineural invasion | 174 | 140 (79.5) |
| High grade | 173 | 49 (27.8) |
| R1 resection margin | 176 | 36 (20.5) |
| AJCC T-stage | 174 | |
| 1 | 8 (4.5) | |
| 2 | 32 (18.2) | |
| 3 | 125 (71.0) | |
| 4 | 9 (5.1) | |
| Lymph node metastasis | 176 | 98 (55.7) |
| Neoadjuvant chemotherapy | 176 | 2 (1.1) |
| Neoadjuvant radiation therapy | 176 | 1 (0.6) |
| Adjuvant chemotherapy | 163 | 107 (60.8) |
| Adjuvant radiation therapy | 161 | 77 (43.8) |
a
Patients with available data; BMI, body mass index; R1, microscopically negative margins; AJCC, American Joint Committee on Cancer.